About two weeks after chikungunya virus (CHIKV) vaccine contender Bavarian Nordic A/S provided phase III data with its prospect, rival Valneva SE rolled out positive phase III safety findings in adolescents with its single-dose candidate VLA-1553. Results from the Saint-Herblain, France-based company’s first trial in an endemic area with people previously infected with CHIKV showed the product was generally safe and well-tolerated in subjects aged 12-17 years, regardless of previous infection by the mosquito-borne disease, carried mainly by Aedes aegypti and Aedes albopictus. Immunogenicity data from the study are expected in November.
Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Free Report) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $6.77 and last traded at $6.94, with a volume of 9101 shares changing hands. The stock had previously closed at $7.09. Bavarian Nordic A/S Stock Performance The business has a […]
Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Free Report) was the target of a large increase in short interest in July. As of July 31st, there was short interest totalling 10,000 shares, an increase of 85.2% from the July 15th total of 5,400 shares. Based on an average daily volume of 39,700 shares, the days-to-cover ratio […]
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22.
Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Free Report)’s share price hit a new 52-week low during trading on Monday . The stock traded as low as $6.92 and last traded at $7.08, with a volume of 96118 shares trading hands. The stock had previously closed at $9.43. Bavarian Nordic A/S Stock Down 24.9 % The […]